DelveInsight

Jan 21, 2016

DelveInsight, the leading market research and consulting company has added new report    “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016”to its portfolio. Reports Highlights: ·      CAR-T cell Therapy Pipeline scenario ·      Collaborations &...

Jan 13, 2016

DelveInsight, the leading market research and consulting company has added new report Zemplar -Drug Insights, 2016 to its portfolio. With this launch DelveInsight now has 400+ Reports on Drug Insight. In addition to this our research expertise provides our clients with up to date information of market till date orde...

Jan 12, 2016

DelveInsight, the leading market research and consulting company has added new report  Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clien...

Jan 12, 2016

DelveInsight, the leading market research and consulting company has added new report   Pancreatic Cancer-Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date i...

Jan 12, 2016

DelveInsight, the leading market research and consulting company has added new report Peripheral Lung Cancer-Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date inf...

Oct 13, 2015

Introduction: Any disease that affects less than 200,000 patients or 1 in 1500 is termed as a rare disease. There are around 5000 to 8000 rare disease reported, out which only 10% have cure. According to the European Organization for rare disease, 80% of rare diseases are genetic in nature. Some of the rare disease...

Sep 01, 2015

Introduction A disease that has not been adopted by the pharmaceutical industry because it provides little financial incentive for the private sector to make and market new medications to treat or prevent it.  An orphan disease may be a rare disease or a common disease that has been ignored because it is far more pr...

Jul 30, 2015

DelveInsight, the leading market research and consulting company has added a new report “Endometrial Cancer - Pipeline Insights, 2015” to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight. In addition to this, our research expertise provides our clients with up to date ...

Jul 30, 2015

DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA).DelveInsight Report, PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015 has received great response and feedback from client...

Jul 30, 2015

Juvenile idiopathic arthritis (JIA) Juvenile idiopathic arthritis (JIA) affects children who are less than 16 years old, commonly occurs in children from the ages of 7 to 12. The disease may occur in adolescents as old as 15 years of age, as well as in infants. Between 10% and 15% of all children with JIA have SJIA....